key: cord-0863837-1gf65b9j
authors: Holt, Anders; Mizrak, Ikram; Lamberts, Morten; Lav Madsen, Per
title: Influence of inhibitors of the renin–angiotensin system on risk of acute respiratory distress syndrome in Danish hospitalized COVID-19 patients
date: 2020-05-07
journal: J Hypertens
DOI: 10.1097/hjh.0000000000002515
sha: 03204eee4f1ac736500aa7676593b63e559297f6
doc_id: 863837
cord_uid: 1gf65b9j

nan

. We looked at a composite outcome of ICU-admission or death and determined the relative risk of RASi in logistic regression models estimating odds ratios of ICU-admission adjusted for time to event or censoring. Out of a total of 2700 PCR positive patients, 689 patients (25.5%) were acutely ill and remained hospitalized for at least 24 h. Of these 689 patients 71.1% were 60 years or older; 58.1% were male; and 32.7% were treated with RASi. Out of 689 patients 525 did not experience an outcome, whereas 164 (23.8%) experienced ICU and/or death ( Table 1) . Eighty-four percent of the patients admitted to ICU needed respirator treatment. Mean risk time from having been admitted for 1 day till ICU was only 2.04 further days (SD 2.29; range 0-10). Medical treatment for chronic obstructive pulmonary disease, statins, antithrombotic drugs, and RASi were equally prevalent among outcome groups, while beta-blockers and spironolactone seem unevenly distributed with higher prevalence among patients, who were admitted to the ICU or died (Table 1) . Glucose-lowering drugs tended to be unevenly distributed between groups (P ¼ 0.087). In logistic regression analyses incorporating sex, age, risk-time, and selected medical treatment, we found that male sex, increasing age, and the use of beta-blockers independently increased odds for ICU-admission or death, but RASi treatment did not.

Current consensus [4, 6] recommends not changing RASi treatment in patients with SARS-CoV-2 infection. Whereas we found other heart failure medication to be of importance, probably mainly reflecting the underlying cardiac phenotype and comorbidity, our data do not suggest any significant influence from chronic RASi treatment and hence our data bring some reassurance to the consensus of not changing RASi medication. Randomized studies on RASi treatment intervention in patients at risk of COVID-19 should consider timing the intervention early in the course of the disease or well before infection, since if patients do develop ARDS they do so after a very short time period.

Baseline characteristics and outcomes of 1591 patients infected with SARS-CoV-2 admitted to ICUs of the Lombardy Region

Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study

Prevalence of comorbidities in the novel Wuhan coronavirus (COVID-19) infection: a systematic review and meta-analysis

Renin-angiotensin-aldosterone system inhibitors in patients with COVID-19

Clinical and biochemical indexes from 2019-nCOV infected patients linked to viral loads and lung injury

Can angiotensin receptor-blocking drugs perhaps be harmful in the COVID-19 pandemic?

There are no conflicts of interest.